Abstract
We previously published results of a pragmatic randomized trial with 3717 participants in Norway that assessed the effect of wearing glasses on the risk of being infected with SARS-CoV-2 and other respiratory infections. Here we present unpublished findings on pre-specified secondary endpoints relying on routinely collected data from Norwegian health registries: Visits to health care providers for any cause (within 21 days), for respiratory symptoms (day 3-28), and for injuries (within 21 days).
1469 participants (39.5%) visited a health care provider for any cause at least once. There was no statistically significant difference between groups, with 39.9.% of participants wearing glasses versus 39.1% in the control group received primary or specialist care (absolute risk difference 0.76%; 95% CI, -2.4% to 3.9%; relative risk 1.02; 95% CI, 0.94 to 1.10).
Similarly, there was no statistically significant difference in visits due to respiratory symptoms (326 participants; 9.1% versus 8.4%; absolute risk difference 0.71%; 95% CI, -1.1% to 2.5%; relative risk 1.08; 95% CI, 0.88 to 1.33).
There were 3 participants having visited primary or specialist care and having an injury registered in a registry for injuries, the difference between groups not statistically significant. The difference between participants in the proportion of visits for injury related diagnoses was nominally statistically significant (1.3% versus 0.7%; absolute risk difference 0.7%; 95% CI, 0.01% to 1.3%; relative risk 1.94; 95% CI, 1.01 to 3.89).
The study underscores the potential of utilizing registry-based outcomes for randomized evaluations of public health measures for infection control.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05217797
Clinical Protocols
https://doi.org/10.1101/2022.07.31.22278223
Funding Statement
the Centre for Epidemic Interventions Research, Norwegian Institute of Public Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the Regional Ethics Committee of South-East Norway (reference no. 428685)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and/or analysed during the current study are not publicly available due to data protection reasons but deidentified participant data are available in from the corresponding author on reasonable request.
